RealDrip - Safer, Simpler and Cheaper Infusion Therapy

A medical device and software as a medical device (SaMD) application that makes blood transfusion and drip treatment simpler, safer and more data-driven. With our platform, called RealDrip, anyone can administer or receive fluid treatment easily and cheaper.

Abdulwaheed Alayande

Approximately 80% of all patients in the hospital setting will receive intravenous therapy (fluid and blood transfusion). IV therapy is used to administer medications, including chemotherapy, anesthetics, and diagnostic reagents: in fact, about 40% of all antibiotics are given intravenously. Remdesivir, intravenous vitamin C, Baricitinib, Casirivimab and imdevimab are few examples of infusion drugs for treating COVID19 Patient. Precise Infusion data point is critical in treatment, management, prediction and clinical research discovery for single patient, epidemic and pandemic. 

Today, largely the infusion treatment process is manual, complex, expensive and time-consuming. Traditional companies tried to solve it with expensive and bulky alternatives, this requires constant re-training of health professionals to follow rigid and complex procedures in those alternatives, which often add to the extra cost of healthcare and leave them devastated. As a result, they often go back to the manual procedures, minimal or no infusion data points for preventive medicine and leave patients at the mercy of human errors.

Our purpose is to save lives by empowering today’s medical team with affordable medical devices and software as a medical device (SaMD) applications. Our solution helps clinicians monitor patients on infusion (blood transfusion and drips) treatment to reduce clinical errors, makes precise and predictive medicine more affordable and analyse critical data points for preventive medicine either for a single patient, epidemic or a pandemic. The product directly improves the planning, process, and productivity of medical personnel, the secondary effect is keeping patients safe since approximately 80% of all patients in the hospital will receive intravenous therapy.

We have spent over 3 years of arduous work interviewing, building and testing the product to validate every hypothesis that we had, this involves working closely with various health stakeholders across the country and a partnership with the Nigerian Institute of Medical Research ( NIMR - the most extensive Federal owned medical research facilities).

We are working on knowledge transfer and active collaboration with public medical research institute such as the Nigerian Institute of Medical Research. We will be publishing peer-review journals.

We are also going to donate some of our devices at free-cost to selected clinics in developing countries.

We took certain features of the RealDrip device and rebuilt it into a standalone mobile app called DripX. We made it completely free for clinics and is currently in use by over 25 clinics to deliver better care, tracking infusion data point and keep patients safer at no cost -https://treplabs.co/dripx

Most health tech companies focus only on making a quick sale to clinics without full understanding of the problems or simplifying their products; clinicians have no choice than to make use of available alternatives to deliver care, which always leaves them devastated. Doctors run clinics, not tech people or engineer, and they are unable to understand the complexities of these clinical products clearly.

We are building our solutions with active collaboration with clinicians to simplify their process, planning, and productivity with the ultimate goal to keep patients safer. Our product is 98% cheaper than the current alternative and uses modern technologies that today's medical team can relate to

We are already working with clinics through word of mouth. We understand the complexity in medical distribution, we are currently working with distribution partners, building out distribution networks and continuously positioning our product for global adoption. 

Number of Treatment completed

Number of Anomalous infusion treatment detection

Number of Patient treatment 

Hours of Clinicians time saved 

Regulatory - Health is a heavily regulated industry and varies across different regions. We have regulatory approval in Nigeria, next is to obtain CE Mark, UK MHRA license, and FDA 510k device clearance. To faster track the process, our preliminary human clinical trials were a multi-ward, gold-standard, and we strictly adhere to IEC 62304 (Functional Safety Standard), ISO 13485 (Quality Management) & ISO 14971 (Risk Management) in our entire product lifecycle.

Manufacturing - Medical devices must ensure safety and quality from the development lab down to the clinicians, including manufacturing. We have identified and working with an FDA-approved manufacturer to ensure quality control pre or post-deployment.

Technical - We operate in an extensive technical environment bringing new and deep technologies to tackle medical problems. We are an experienced team in building complex technologies to simplify medical problems and ultimately save lives at cheaper costs.

Distribution - Medical distribution requires a deep root system for clinicians and medical facilities. We are working with medical research institutes, medical distributors and actively open to collaboration from relevant stakeholders. 

We want access to the mentorship, exposure and network that comes with The Trinity Challenge and Trinity Challenge Member organisations. Trinity Challenge Members’ interest in healthcare and success in transforming healthcare companies particularly influenced our decision to apply.

Our plan is to conduct clinical research in the UK, obtain CE mark, FDA approval next. Leveraging the Challenge Members' deep root in the UK and US, and expertise in guiding healthcare startups, we are confident to receive the necessary guidance to navigate the process. Reaching some corporate partners and stakeholders is a difficult challenge, we hope to overcome the barrier through The Trinity Challenge Network.

We believe that we can 20x our impact and growth both as a company and as founders by joining the Trinity Challenge.

We would like to have a mutually-beneficial partnership with corporate entities in healthcare especially intravenous drugs manufacturer, medical research institutes, universities to leverage their expertise, distribution network, and broaden our understanding of value-creation for sustainable health impact. 

We also hope to work with the partner universities faculty for mentorship and access to advanced prototyping tools to help accelerate R&D and further help us to create better products at a lower cost to reach a large measurable impact.